MSL Talk
MSL Talk, hosted by Tom Caravela, MSL Recruiter and Founder of The Carolan Group, offers insights for Medical Science Liaisons, aspiring MSLs, and Medical Affairs leaders.
Is it Ever Too Early or Too Late
In this episode, Tom Caravela is joined by Jeff Vaughn and Dean McAllister to discuss the critical timing of Medical Science Liaison (MSL) involvement in drug development. They explore misconceptions and historical approaches, highlighting the impact and internal value of early MSL engagement. The conversation addresses challenges MSLs face, the adaptation to virtual engagement, and the importance of strategic prioritization within a global framework. They delve into the integration of AI and long-term clinical trial planning, emphasizing the need to bridge theory and practice. The episode concludes with insights on networking among industry leaders and sponsor appreciation.
Key Points
- Involving MSLs and subject matter experts early in the drug development process can significantly enhance trial design, patient recruitment, and overall clinical strategy.
- MSLs provide critical insights and establish valuable relationships with KOLs and HCPs, which can accelerate trial accrual and improve the quality of the clinical data collected.
- A strategic framework for involving MSLs should include scalable deployment, prioritization of key territories, and a consistent global approach to ensure alignment and maximize impact throughout the product lifecycle.
Chapters
| 0:00 | |
| 1:08 | |
| 1:23 | |
| 1:51 | |
| 3:52 | |
| 7:00 | |
| 11:59 | |
| 19:28 | |
| 23:39 | |
| 27:12 | |
| 28:02 | |
| 31:00 | |
| 32:53 |
Transcript
Loading transcript...
- / -